Payment overview · 2025
General Payments
$150.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Priya Rajkumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1942400379
Verified facts
What the public records show
CMS Open Payments records show Priya Rajkumar, MD received $150.00 in general payments during 2025 across 1 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $150.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 100 |
| Metformin Hcl | Metformin Hcl | 235 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 227 | 43 |
| Gabapentin | Gabapentin | 208 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 63 |
| Omeprazole | Omeprazole | 160 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 43 |
| Losartan Potassium | Losartan Potassium | 139 | 45 |
| Furosemide | Furosemide | 127 | 36 |
| Glipizide | Glipizide | 127 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 49 |
| Baclofen | Baclofen | 111 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 30 |
| Ibuprofen | Ibuprofen | 100 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 29 |
| Ozempic | Semaglutide | 81 | 21 |
| Jardiance | Empagliflozin | 79 | 26 |
| Trulicity | Dulaglutide | 78 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 25 |
| Famotidine | Famotidine | 70 | 27 |
| Sertraline Hcl | Sertraline Hcl | 70 | 18 |
| Lisinopril | Lisinopril | 67 | 25 |
| Fosinopril Sodium | Fosinopril Sodium | 61 | 17 |
| Lorazepam | Lorazepam | 57 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 23 |
| Clotrimazole | Clotrimazole | 49 | 19 |
| Metformin Hcl Er | Metformin Hcl | 49 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 23 |
| Atenolol | Atenolol | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 14 |
| Montelukast Sodium | Montelukast Sodium | 39 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 16 |
| Carvedilol | Carvedilol | 38 | 14 |
| Atrovent Hfa | Ipratropium Bromide | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 35 | 15 |
| Simvastatin | Simvastatin | 35 | 13 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Finasteride | Finasteride | 24 | 13 |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tretinoin | Tretinoin | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.00 · 1 records | SANOFI-AVENTIS U.S. LLC | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error